Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model

Clinical trials are studying the benefits of combining the PARP-1 inhibitor olaparib with chemotherapy and radiotherapy treatment in a variety of cancer increasing the therapeutic ratio for olaparib may come from its ability to modify the tumour microenvironment by targeting homologous recombination...

Descripción completa

Detalles Bibliográficos
Autores principales: Borst, Gerben R., Kumareswaran, Ramya, Yücel, Hatice, Telli, Seyda, Do, Trevor, McKee, Trevor, Zafarana, Gaetano, Jonkers, Jos, Verheij, Marcel, O’Connor, Mark J., Rottenberg, Sven, Bristow, Robert G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5675659/
https://www.ncbi.nlm.nih.gov/pubmed/29152107
http://dx.doi.org/10.18632/oncotarget.20936

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5675659/
https://www.ncbi.nlm.nih.gov/pubmed/29152107
http://dx.doi.org/10.18632/oncotarget.20936

Ejemplares similares